Phase i dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 598-603

  Freyer, G ^a   Isambert, N ^b,c   You, B ^a   Zanetta, S ^b,c   Falandry, C ^a   Favier, L ^b   Trillet Lenoir, V ^a   Assadourian, S ^d   Soussan Lazard, K ^d   Ziti Ljajic, S ^d   Fumoleau, P ^b,c  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d SANOFI   (France)

Author keywords

aflibercept; angiogenesis; anti VEGF therapy; VEGF trap

Indexed keywords

AFLIBERCEPT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECTUM CANCER; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SYSTOLIC HYPERTENSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RECOMBINANT FUSION PROTEINS; TAXOIDS;

EID: 84864883075     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.304     Document Type: Article

References (25)

1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47: 8-32
2. Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16: 187-196
3. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9: 5721-5728
4. Chang PM, Tzeng CH, Chen MH, Tsao CJ, Su WC, Hwang WS, Chang YF, Chang SY, Yang MH (2011) Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemother Pharmacol 68(6): 1477-1484
5. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29: 10-14
6. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024
7. Fukasawa M, Korc M (2004) Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 10: 3327-3332
8. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24: 4963-4970
9. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027
10. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398
11. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ (2003) Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100: 7785-7790
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
13. Isambert N, Freyer G, Zanetta S, You B, Fumoleau P, Falandry D, Favier L, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Trillet-Lenoir V (2011) Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 18(6): 1743-1750
14. Lal D, Park JA, Demock K, Marinaro J, Perez AM, Lin MH, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES (2010) Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol Cancer Ther 9: 2737-2751
15. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM (2011) Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 10: 1326-1333
16. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS (2010) A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5: 1054-1059
17. Leujeune P, Chiron M, Le Moigne R, Vrignaud P, Bissery M-C (2008) Combination of the antiangiogenic agent aflibercept (VEGF Trap) with docetaxel or gemcitabine results in greater antitumor activity in tumor bearing mice. Proc Am Assoc Can Res 12: (abstract 1107)
18. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28: 207-214
19. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247
20. Regeneron Pharmaceuticals Inc. Press release. Sanofi-aventis and Regeneron report top-line results from the phase III study with aflibercept (VEGF Trap) in second-line non-small cell lung cancer. http://newsroom. regeneron.com/releasedetail.cfm?ReleaseID=556162 (2011) (accessed June 2011)
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550
22. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28: 3299-3306
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
24. Van Cutsem E, Tabernero J, Lakomy R, Prausova J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, McKendrick J, Tellier A, Castan R, Allegra C (2011) Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC 10262-VELOUR). Ann Oncol 22(Suppl 5): v18 (abstract O-0024)
25. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R (2007) Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208